文献速递冠心病心力衰竭与心肌病心律失常

2010至2017年女性在心血管临床试验中的参与情况

Women's Participation in Cardiovascular Clinical Trials From 2010 to 2017.
PubMed 文献 · Circulation · 2020-02-17

女性与男性比值中位数为0.51,且随年龄、干预类型、疾病类型、地区、资助类型和试验规模变化;高血压和肺动脉高压的参与患病率比值高于0.8,而心律失常、冠心病、急性冠脉综合征和心力衰竭较低;2013至2017年卒中和心力衰竭试验的参与患病率比值显著增加。

要点

  • 女性在心血管试验中仍占少数,总体占比38.2%,女男比值中位数0.51。
  • 参与程度因疾病而异:高血压和肺动脉高压代表性较好,冠心病、心衰等较低。
  • 卒中和心衰试验的女性参与患病率比值在2013至2017年显著改善。

核心结论

  • 当前十年心血管试验中男性仍占主导,但女性代表性随疾病和试验特征变化,且在卒中和心衰试验中有所改善。

主要发现

  • 女性占全部参与者的38.2%,各试验女男比值中位数为0.51(25百分位0.32,75百分位0.90)。
  • 女男比值随年龄组变化:≤55岁组为1.02,61-65岁组为0.40。
  • 女男比值随干预类型变化:操作干预试验为0.44,生活方式干预试验为0.78。
  • 女男比值随疾病类型变化:急性冠脉综合征为0.34,肺动脉高压为3.20。
  • 参与患病率比值高于0.8见于高血压和肺动脉高压;较低(0.48至0.78)见于心律失常、冠心病、急性冠脉综合征和心力衰竭试验。

临床怎么用

  • 解读心血管试验结果时需考虑女性代表性不足对结论外推的影响。
  • 在女性代表性较低的疾病领域(如冠心病、心衰)应关注性别差异证据的局限性。
  • 卒中与心衰试验的女性参与改善提示可借鉴其招募策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiovascular disease is the leading cause of death among women worldwide, yet, women have historically been underrepresented in cardiovascular trials. METHODS: We systematically assessed the participation of women in completed cardiovascular trials registered in ClinicalTrials.gov between 2010 and 2017, and extracted publicly available information including disease type, sponsor type, country, trial size, intervention type, and the demographic characteristics of trial participants. We calculated the female-to-male ratio for each trial and determined the prevalence-adjusted estimates for participation of women by dividing the percentage of women among trial participants by the percentage of women in the disease population (participation prevalence ratio; a ratio of 0.8 to 1.2 suggests comparable prevalence and good representation). RESULTS: We identified 740 completed cardiovascular trials including a total of 862 652 adults, of whom 38.2% were women. The median female-to-male ratio of each trial was 0.51 (25th quartile, 0.32; 75th quartile, 0.90) overall and varied by age group (1.02 in ≤55 year old group versus 0.40 in the 61- to 65-year-old group), type of intervention (0.44 for procedural trials versus 0.78 for lifestyle intervention trials), disease type (0.34 for acute coronary syndrome versus 3.20 for pulmonary hypertension), region (0.45 for Western Pacific versus 0.55 for the Americas), funding/sponsor type (0.14 for government-funded versus 0.73 for multiple sponsors), and trial size (0.56 for smaller [n≤47] versus 0.49 for larger [n≥399] trials). Relative to their prevalence in the disease population, participation prevalence ratio was higher than 0.8 for hypertension, pulmonary arterial hypertension and lower (participation prevalence ratio 0.48 to 0.78) for arrhythmia, coronary heart disease, acute coronary syndrome, and heart failure trials. The most recent time period (2013 to 2017) saw significant increases in participation prevalence ratios for stroke (P=0.007) and heart failure (P=0.01) trials compared with previous periods. CONCLUSIONS: Among cardiovascular trials in the current decade, men still predominate overall, but the representation of women varies with disease and trial characteristics, and has improved in stroke and heart failure trials.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Jin X, Chandramouli C, Allocco B, et al. Women's Participation in Cardiovascular Clinical Trials From 2010 to 2017. Circulation. 2020. PMID: 32065763. doi:10.1161/CIRCULATIONAHA.119.043594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。